Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains who the target population is for cabotegravir. Dr. Rinehart stresses that essentially, anyone who is at risk for HIV can use cabotegravir as a preventive option against the virus.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512